Best Nutraceutical Product 

GENERAL ELIGIBILITY CRITERIA FOR GREECE 

With a focus on research into naturally occurring biomolecules, an increasing number of companies are pioneering the development and clinical validation of specially designed nutraceuticals. Through investment in research and clinical studies, these innovative products contribute both to patient stabilization, serving as a supportive measure against chronic and autoimmune diseases, and to the management of symptoms, thereby helping to improve patients’ quality of life. 

Nutraceuticals differ from conventional dietary supplements in their intended purpose and potential therapeutic application. 

• Nutraceuticals are intended not only to supplement the diet but also to provide specific physiological and/or therapeutic benefits, including potential applications in the prevention and/or management of disease. 

• Nutraceuticals may comprise a single bioactive compound or a defined combination of bioactive ingredients. Their development and use are increasingly supported by scientific research and clinical evidence aimed at achieving specific health or therapeutic outcomes while potentially minimizing adverse effects compared with conventional therapeutic interventions. 

The therapeutic potential of bioactive compounds derived from natural sources is gaining increasing scientific and clinical interest, particularly in the context of chronic diseases and conditions in which nutritional and pharmacological approaches may complement one another. 

Products submitted for consideration for the Prix Galien Greece 2027 Awards must have received marketing authorization in Greece between January 1st 2022 and April 30th 2026, inclusive. 

QUALITATIVE CRITERIA 

Candidate products may belong to any therapeutic category. However, the Awards will be conferred to those products that contribute to improving patients’ quality of life or saving lives, based on the following two criteria: 

1. What degree of innovation was demonstrated throughout the scientific development of the product, including its mechanism of action and clinical utility? 

1. What is the potential contribution of the product to the future advancement of medical science through its introduction into clinical practice? 

Only one winner shall be selected in each Award category. However, in the event of a tie involving one or more candidates, the Jury shall have the right to designate an additional winner under the Hors Prix distinction. 

ELIGIBILITY CRITERIA 

• Product originality and innovation — the product should demonstrate a distinctive formulation or innovative approach and should not represent another nutraceutical with substantially equivalent composition or intended use. 

• Clinical evidence — clinical studies supporting the beneficial effects of the product in specific health conditions. 

• Population-specific evidence — relevant studies, where available, targeting specific population groups. 

• Enhanced bioavailability — formulations or dosage forms demonstrating improved bioavailability. 

SPECIFIC ELIGIBILITY CRITERIA FOR GREECE 

1. Summary of the Submission (up to 1 page)

This section should provide a concise summary outlining the product’s principal indications and the key elements of the nomination submission. 

2. Rationale and Product Development (up to 3 pages)

This section should include: 

• A description of how and why the product was developed. 

• Whether the product has a unique and clearly defined therapeutic objective. 

• Whether innovative development techniques were employed in the development of the product. 

3. Clinical Evaluation (up to 2 pages)

This section should provide a summary of the clinical development programme, including key information on the product’s mechanism of action, dosing regimen, and clinical trial design. 

The submission may include information from up to 10 peer-reviewed publications. 

4. Conclusions (up to 1 page)

This section is optional. However, applicants may wish to include conclusions highlighting the key advantages and potential benefits of the product. 

5. Page Formatting Requirements

The total length of the submission for each Award category must not exceed 12 A4 pages, using 1.5 line spacing, 12-point Arial font, and 2 cm margins on all sides. 

All supporting documentation and certificates must be submitted electronically together with the awards application online form.   

APPLICATION FEES 

For further information regarding the application fee and the benefits associated with your nomination for the “Best Nutraceutical Product”, please contact us at info@jpcom.gr or by phone at +30 210 813 2828 or +30 210 813 2366. 

Best Pharmaceutical Product 

Best Biotechnology Product 

Best Product for Rare Disease 

Best Medical Technology Product 

GENERAL ELIGIBILITY CRITERIA FOR GREECE 

Pharmaceutical and biotechnology products evaluated by the Prix Galien Greece Awards must be based on innovation and developed using chemical, biological, or biotechnological processes. Applicants must provide detailed and accurate specifications regarding the products’ manufacturing processes, as well as the results of their clinical trials. 

Products submitted for consideration must have received marketing authorization in Greece—including approval of the relevant indication, but not necessarily pricing approval—through a centralised, national, or mutual recognition procedure, between January 1st  2022 and April 30th 2026, inclusive. 

The above criteria also apply to previously approved products that have subsequently received approval for a new, innovative indication or a new therapeutic benefit (NTE – New Therapeutic Entity), provided that such approval has been granted within the preceding four (4) years. 

Regarding the Medical Technology Products category, products submitted for consideration must have received marketing authorization in Greece between January 1st 2025 and April 30th 2026, inclusive. 

QUALITATIVE CRITERIA 

Candidate products may belong to any therapeutic category. However, the Awards will be conferred to those products that contribute to improving patients’ quality of life or saving lives, based on the following two criteria: 

1. What was the degree of innovation demonstrated throughout the scientific development of the product, including its mechanism of action and clinical utility? 

1. What is the potential contribution of the product to the future advancement of medical science through its introduction into clinical practice? 

Only one winner shall be selected in each Award category. However, in the event of a tie between two or more candidates, the Jury reserves the right to designate a second winner under the Hors Prix distinction. 

The following factors shall not be taken into consideration in the evaluation process: market size (including the number of cases or product sales), company size, development costs, or any other factors related to product distribution that are beyond the applicant’s control. 

Best Pharmaceutical Product 

Best Biotechnology Product 

Best Product for Rare Disease 

SPECIAL ELIGIBILITY AND SUBMISSION CRITERIA FOR GREECE 

Products eligible for consideration in this category must be approved in the European Union and commercially available in Greece. 

Proposal Summary — up to 1 page 

The proposal should begin with a concise summary outlining the product’s principal indications and highlighting the key elements of the nomination. 

Rationale and Innovation — up to 3 pages 

This section should address the following: 

• The background and rationale behind the development of the product, including how and why it was developed. 

• Whether the product addresses a unique and clearly defined therapeutic target. 

• The use of innovative technologies or approaches in the development of the product. 

• The originality and innovative aspects of its chemical or biotechnological development. 

Clinical Evaluation — up to 2 pages 

This section should provide a summary of the clinical development programme, including the key elements relating to: 

• The product’s mechanism of action. 

• The dosing regimen. 

• The design and methodology of the clinical trials. 

The submission may include information from up to 10 peer-reviewed publications. 

Conclusions — up to 1 page 

This section is optional. Applicants may, however, wish to provide a concise summary of the product’s key strengths, advantages and added value. 

Submission and Formatting Requirements 

The total length of the nomination dossier for each award category must not exceed 12 A4 pages. 

The document should be prepared using: 

• 12-point Arial font 

• 1.5 line spacing 

• 2 cm margins 

All supporting documentation and relevant certificates must be submitted electronically together with the awards application online form.   

APPLICATION FEES 

For further information regarding the application fee and the benefits associated with your nomination for the “Best Pharmaceutical Product”, please contact us at info@jpcom.gr or by phone at +30 210 813 2828 or +30 210 813 2366. 

For further information regarding the application fee and the benefits associated with your nomination for the “Best Biotechnology Product”, please contact us at info@jpcom.gr or by phone at +30 210 813 2828 or +30 210 813 2366. 

For further information regarding the application fee and the benefits associated with your nomination for the “Best Product for rare Disease”, please contact us at info@jpcom.gr or by phone at +30 210 813 2828 or +30 210 813 2366. 

Best Medical Technology Product 

SPECIAL ELIGIBILITY AND SUBMISSION CRITERIA FOR GREECE 

Products eligible for consideration in this category must have received certification from a European Notified Body and be commercially available in Greece. 

Proposal Summary — 1 page 

The proposal should begin with a concise summary outlining the product’s principal indications and highlighting the key elements of the nomination. 

Rationale and Innovation — 3 pages 

This section should address the following: 

• The background and rationale behind the design and development of the product, including how and why it was developed. 

• The key areas in which the product offers advantages over previously available products in the same category, with regard to its technological design, application, method of use, ease of use, reliability, accuracy and effectiveness. 

• The use of innovative technologies or techniques in the design and development of the product. 

Impact on Population Health — 5 pages 

This section should address the following: 

• The anticipated market size and market penetration. 

• Comparisons with key competing products. 

• The anticipated impact on patients. 

• The estimated contribution and benefits to public health. 

Conclusions — 1 page 

This section is optional. Applicants may, however, wish to provide a concise summary of the product’s key strengths, advantages and added value. 

Application Summary — 1 page 

This section should: 

1. a)Provide the reader with a clear overview of the product’s key characteristics relevant to its intended indication and innovative features.
2. b)Include details regarding the product’s regulatory authorisation, including, where applicable, whether the authorisation is granted for a limited period and/or subject to specific conditions.
3. c)State whether the product is currently subject to any safety-related regulatory appeal or review by theEuropean Medicines Agency (EMA). 

ubmission and Formatting Requirements 

The total length of the nomination dossier for each award category must not exceed 20 A4 pages. 

The document should be prepared using: 

• 12-point Arial font 

• 1.5 line spacing 

• 2 cm margins 

All supporting documentation and relevant certificates must be submitted  electronically together with the awards application online form.   

APPLICATION FEES 

For further information regarding the application fee and the benefits associated with your nomination for the “Best Medical Technology Product”, please contact us at info@jpcom.gr or by phone at +30 210 813 2828 or +30 210 813 2366.